Two-Face molecule could help make IBD treatments more effective

A drug that targets an overactive immune response may also weaken the gut’s ability to fight harmful bacteria. Understanding where the molecule, RelB, is helping or not could be important before this pathway is considered for treatment, new research from National Institute of Immunology, New Delhi, has found.

Deep within the intestinal wall, beyond where digestion and nutrient absorption occur, are immune outposts called solitary isolated lymphoid tissues, or SILTs. These structures host cells that govern how aggressively the gut reacts to microbes. A wea... [5875 chars]